Market Overview

UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical Ahead of GALNS Data

Share:
Related BMRN
Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey
Your Guide To 2017's Emerging Pharmaceuticals Catalysts
Marketplace Roundtable: Biotech Hanging In The Balance (Seeking Alpha)

Jefferies reiterated its Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN) and raised its price target from $44 to $46.

Jefferies said, "Our experts discussions indicate probability of successful GALNS Ph3 for Morquio A syndrome (MPS IV) at ~60%-85%. If successful, we forecast ~25-30% upside from current levels (& BMRN will likely continue to trade up on additional pipeline potential). BMRN expects GALNS BLA filing in 1Q13, with potentially regulatory approval by 4Q13. We forecast GALNS to turn BMRN to profitability, with peak annual sales potential of ~$500M."

BioMarin Pharmaceutical closed at $38.87 on Tuesday.

Latest Ratings for BMRN

DateFirmActionFromTo
Mar 2017NomuraInitiates Coverage OnNeutral
Feb 2017Morgan StanleyInitiates Coverage OnOverweight
Jan 2017Credit SuisseAssumesOutperformOutperform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BMRN)

View Comments and Join the Discussion!